Development of the first geldanamycin-based HSP90 degraders
Open Access
- 28 June 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Chemistry
- Vol. 11, 1219883
Abstract
Despite the early clinical promise, adverse events such as acquired resistance and dose-limiting toxicities have barred the widespread use of HSP90 inhibitors as anticancer drugs. A new approach involving proteolysis-targeting chimeras (PROTACs) to degrade the protein instead of inhibiting it may overcome these problems. In this work, we describe the design, synthesis, and evaluation of cereblon-recruiting geldanamycin-based HSP90 degraders based on the PROTAC technology. Our best degrader, 3a, effectively decreased HSP90α and HSP90β levels in cells utilizing the ubiquitin–proteasome pathway.Keywords
This publication has 25 references indexed in Scilit:
- Maximizing the Therapeutic Potential of HSP90 InhibitorsMolecular Cancer Research, 2015
- Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directionsExpert Opinion on Investigational Drugs, 2014
- The Therapeutic Target Hsp90 and Cancer HallmarksCurrent Pharmaceutical Design, 2013
- Hsp90: Structure and Function2012
- Synthesis of novel fluorescent probes for the molecular chaperone Hsp90Bioorganic & Medicinal Chemistry Letters, 2003
- Synthesis and evaluation of geldanamycin–testosterone hybridsBioorganic & Medicinal Chemistry Letters, 2000
- Molecular chaperones: The busy life of Hsp90Current Biology, 1999
- Synthesis and evaluation of geldanamycin-estradiol hybridsBioorganic & Medicinal Chemistry Letters, 1999
- The 90-kDa Molecular Chaperone FamilyPharmacology & Therapeutics, 1998
- GELDANAMYCIN, A NEW ANTIBIOTICThe Journal of Antibiotics, 1970